Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study.

@article{Bissonnette2017OlumacostatGA,
  title={Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study.},
  author={Robert Bissonnette and Yves P Poulin and Janice Drew and Hans E J Hofland and J Tan},
  journal={Journal of the American Academy of Dermatology},
  year={2017},
  volume={76 1},
  pages={33-39}
}
BACKGROUND Olumacostat glasaretil (OG) inhibits acetyl-coenzyme A carboxylase, the enzyme responsible for the first, rate-limiting step in de novo fatty acid synthesis. OG inhibited in vitro human sebocyte lipid production and reduced in vivo sebaceous gland size in hamster ears. OBJECTIVES Safety and efficacy of OG 7.5% gel were evaluated in patients with moderate to severe facial acne vulgaris. METHODS Patients were randomized (1:1) to twice-daily application of OG or vehicle for 12 weeks… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-2 of 2 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 15 references

DRM01, a novel acetyl coenzyme A carboxylase (ACC) inhibitor, reduces sebum production

Hunt DWC, Hofland HEJ
J Invest Dermatol • 2014
View 2 Excerpts

European evidence-based (S3) guidelines for the treatment of acne.

Journal of the European Academy of Dermatology and Venereology : JEADV • 2012
View 3 Excerpts

New treatments and therapeutic strategies for acne.

Archives of family medicine • 2000
View 1 Excerpt

Similar Papers

Loading similar papers…